DK1061803T3 - Eprosartansammensætninger - Google Patents

Eprosartansammensætninger

Info

Publication number
DK1061803T3
DK1061803T3 DK99909780.1T DK99909780T DK1061803T3 DK 1061803 T3 DK1061803 T3 DK 1061803T3 DK 99909780 T DK99909780 T DK 99909780T DK 1061803 T3 DK1061803 T3 DK 1061803T3
Authority
DK
Denmark
Prior art keywords
eprosartan
compositions
composition
solvate
hydrate
Prior art date
Application number
DK99909780.1T
Other languages
English (en)
Inventor
Gopadi M Venkatesh
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Application granted granted Critical
Publication of DK1061803T3 publication Critical patent/DK1061803T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
DK99909780.1T 1998-03-11 1999-03-11 Eprosartansammensætninger DK1061803T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7766098P 1998-03-11 1998-03-11
PCT/US1999/004651 WO1999045779A1 (en) 1998-03-11 1999-03-11 Novel compositions of eprosartan

Publications (1)

Publication Number Publication Date
DK1061803T3 true DK1061803T3 (da) 2011-08-29

Family

ID=22139347

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99909780.1T DK1061803T3 (da) 1998-03-11 1999-03-11 Eprosartansammensætninger

Country Status (21)

Country Link
EP (1) EP1061803B1 (da)
JP (1) JP2002506010A (da)
KR (1) KR20010041796A (da)
CN (1) CN1299235A (da)
AT (1) ATE508633T1 (da)
AU (1) AU757547B2 (da)
BR (1) BR9908691A (da)
CA (1) CA2323363C (da)
CY (1) CY1111738T1 (da)
CZ (1) CZ303067B6 (da)
DK (1) DK1061803T3 (da)
ES (1) ES2366394T3 (da)
HU (1) HU228574B1 (da)
IL (1) IL138345A (da)
NO (1) NO331207B1 (da)
NZ (1) NZ506700A (da)
PL (1) PL192545B1 (da)
SI (1) SI1061803T1 (da)
TR (1) TR200002646T2 (da)
WO (1) WO1999045779A1 (da)
ZA (1) ZA991922B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0810853B1 (en) 1995-02-24 2004-08-25 Elan Pharma International Limited Aerosols containing nanoparticle dispersions
JP4575594B2 (ja) * 1998-07-20 2010-11-04 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 経口用固体剤形のエプロサルタン配合の生体内強化性処方
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
BR0110079A (pt) * 2000-04-12 2002-12-31 Novartis Ag Combinação de compostos orgânicos
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
EP1382334A1 (en) * 2002-07-11 2004-01-21 Université de Picardie Jules Verne Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke
AU2004206109A1 (en) * 2003-01-21 2004-08-05 Ranbaxy Laboratories Limited Co-precipitated amorphous losartan and dosage forms comprising the same
KR101194453B1 (ko) 2003-01-31 2012-10-24 다이이찌 산쿄 가부시키가이샤 동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약
EP1776095A1 (en) * 2004-06-23 2007-04-25 Solvay Pharmaceuticals GmbH Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and at1-receptor antagonists
US20060099230A1 (en) * 2004-11-10 2006-05-11 Chin-Chih Chiang Novel formulations of eprosartan with enhanced bioavailability
WO2006136916A2 (en) * 2005-06-20 2006-12-28 Glenmark Pharmaceuticals Limited Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same
KR100715355B1 (ko) * 2005-09-30 2007-05-07 주식회사유한양행 프란루카스트를 함유하는 분무-건조 과립 및 그의 제조방법
WO2009013760A2 (en) * 2007-07-25 2009-01-29 Hetero Drugs Limited Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan
EP2108365A1 (en) * 2008-04-09 2009-10-14 LEK Pharmaceuticals d.d. Single dosage pharmaceutical formulation comprising eprosartan mesylate
CN103705510A (zh) * 2013-12-27 2014-04-09 华润赛科药业有限责任公司 一种阿齐沙坦固体组合物的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
JPS587609B2 (ja) 1979-06-17 1983-02-10 フロイント産業株式会社 粉体薬剤のコ−テング法
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
JP2642486B2 (ja) 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DK0889880T3 (da) * 1996-03-29 2003-09-01 Smithkline Beecham Corp Eprosartan-dihydrat og fremgangsmåde til fremstilling deraf samt formulering
ES2273433T3 (es) * 1997-08-06 2007-05-01 Smithkline Beecham Corporation Complejo por neutralizacion de cargas con arginilo de eprosartan y procedimiento para su produccion y formulacion.

Also Published As

Publication number Publication date
ES2366394T3 (es) 2011-10-19
HUP0101243A1 (hu) 2002-05-29
NO331207B1 (no) 2011-10-31
CY1111738T1 (el) 2015-10-07
HUP0101243A3 (en) 2005-09-28
ATE508633T1 (de) 2011-05-15
CA2323363A1 (en) 1999-09-16
IL138345A0 (en) 2001-10-31
CZ303067B6 (cs) 2012-03-21
IL138345A (en) 2004-12-15
HU228574B1 (en) 2013-04-29
CA2323363C (en) 2008-09-30
BR9908691A (pt) 2000-12-26
CZ20003288A3 (cs) 2001-03-14
NO20004502D0 (no) 2000-09-08
EP1061803A4 (en) 2007-12-26
ZA991922B (en) 1999-09-13
TR200002646T2 (tr) 2001-01-22
EP1061803B1 (en) 2011-05-11
WO1999045779A1 (en) 1999-09-16
PL192545B1 (pl) 2006-11-30
CN1299235A (zh) 2001-06-13
PL343411A1 (en) 2001-08-13
NO20004502L (no) 2000-11-07
AU2890999A (en) 1999-09-27
JP2002506010A (ja) 2002-02-26
KR20010041796A (ko) 2001-05-25
EP1061803A1 (en) 2000-12-27
AU757547B2 (en) 2003-02-27
NZ506700A (en) 2003-03-28
SI1061803T1 (sl) 2011-09-30

Similar Documents

Publication Publication Date Title
CY1111738T1 (el) Συνθeσεις επροσαρτανης
CA2338256A1 (en) Bioenhanced formulations comprising eprosartan in oral solid dosage form
MY127793A (en) Novel form of s-omeprazole.
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
MXPA05005296A (es) Bis-aril sulfonamidas.
HK1058934A1 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
NO20013444D0 (no) Triazolforbindelser med dopamin-D3-reseptor-affinet
JO2481B1 (en) Silo cano-indol compounds have fluoride substitution and formulations containing such compounds and their treatment methods
DE69928655D1 (de) Substituierte porphyrine
MY117682A (en) Eprosartan dihydrate and a process for its production and formulation
ATE219074T1 (de) Neue salzform von pantoprazol
PL343467A1 (en) Heterocyclically substituted amides, their production and their use
WO2006052461A3 (en) Novel formulations of eprosartan with enhanced bioavailability
NO20031033L (no) Reseptor i EDb-fibronectindomene
MY120085A (en) Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines.
EA200300850A1 (ru) Применение антагонистов рецептора gal3 при лечении депрессии и/или тревоги и соединения, полезные в таких способах
FR2842516B1 (fr) Composition d'ensimage pour verranne, procede utilisant cette composition et produits resultants